17 June 2027 · Princeton, New Jersey

Drug Discovery Innovation Programme

One focused day of insight and connection — keynotes, case studies and partner slots.

Refine the schedule Find sessions by type, topic, speaker, or time

Conference theme The Drug Discovery Bottleneck: Solving the Challenges from Target Validation to Clinical Translation
08:00 – 08:50

Bright Start: Welcome Coffee, Registration & Itinerary Collection

08:50 – 08:55

Welcome Note from World BI

08:55 – 09:00

Chairperson Welcome Address

Chairperson
Igor Nasonkin PhD
Igor Nasonkin PhD Co-Founder & CEO · Phythera Therapeutics, Inc
09:00 – 09:25
Opening Presentation

Closing the Human Biology Gap: Building More Predictive Preclinical Models

  • Improving the human relevance of preclinical models for better translation
  • Using organoids, human tissues, 3D models and advanced in vitro systems to capture disease biology
  • Identifying where current models fail and how next-generation approaches can improve prediction

Speaker to be announced

09:25 – 09:50
Strategic Discussion

New Modalities, New Challenges: What Does It Take to Build a Clinically Viable Medicine?

  • Translating emerging modalities from scientific promise into viable therapeutic candidates
  • Addressing challenges in efficacy, selectivity, delivery, safety and manufacturability
  • Understanding what differentiates promising new modalities from clinically viable medicines
Panellist
Sreeti Roy Ph.D
Sreeti Roy Ph.D VP/Head of CMC · TMI Therapeutics
09:50 – 10:05
Partner Slot 1

TBC

Partner to be announced

10:05 – 10:55

Coffee Break & Networking Session

10:55 – 11:20
Presentation 1

AI in Drug Discovery: From Prediction to Experimental Validation

  • Applying AI and machine learning to target identification, molecular design and drug discovery decisions
  • Moving beyond computational predictions toward experimentally validated results
  • Integrating AI with biological data and laboratory workflows to improve discovery efficiency

Speaker to be announced

11:20 – 11:40
Partner Slot 2

TBC

Partner to be announced

11:40 – 12:05
Deep Dive Session

The Lead Optimization Challenge: Balancing Potency, Selectivity, Exposure & Developability

  • Optimising potency and selectivity without compromising pharmacokinetic properties
  • Managing ADME, exposure and physicochemical liabilities during lead optimisation
  • Making better candidate-selection decisions through multiparameter optimisation

Speaker to be announced

12:05 – 12:25
Partner Slot 3

TBC

Partner to be announced

12:25 – 13:00
Problem Solution Matrix

Predicting Human Safety Earlier: Why Preclinical Safety Signals Still Fail to Protect Clinical Programs

  • Understanding why preclinical safety findings do not always predict human outcomes
  • Improving early identification of toxicity and safety liabilities
  • Integrating translational models and safety data into earlier development decisions
Panellist
Rakesh Dixit, Ph.D., DABT
Rakesh Dixit, Ph.D., DABT Co-founder, President and CSO · Regio Biosciences
13:00 – 14:00

Luncheon and Networking

14:00 – 14:25
Fireside Chat

AI + Human Expertise: Where Should We Trust Algorithms and Where Do Scientists Still Need to Lead?

  • Defining where AI can enhance scientific decision-making and where human judgement remains essential
  • Managing model uncertainty, bias and explainability in drug discovery
  • Building effective human–AI workflows that combine computational speed with scientific expertise

Speaker to be announced

14:25 – 14:40
Partner Slot 4

TBC

Partner to be announced

14:40 – 15:10
Strategic Discussion

Crossing the Biotech Valley of Death: De-Risking Early Programs for the Next Investment Milestone

  • Identifying the scientific and development risks that prevent promising programmes from progressing
  • Building stronger evidence packages to reach the next funding or development milestone
  • Aligning scientific validation, development strategy and investor expectations to improve programme success

Speaker to be announced

15:10 – 16:00

Coffee Break & Networking Session

16:00 – 16:25
Presentation 2

Target Validation in Complex Biology: From Biological Association to Therapeutic Confidence

  • Moving from genetic and biological associations to functional evidence of target relevance
  • Strengthening target validation across disease models and biological contexts
  • Improving confidence in target selection before major discovery investment
Speaker
Felix Sheinerman
Felix Sheinerman EVP, Head of Discovery Research · Mintellium Therapeutics Inc
16:25 – 16:40
Partner Slot 5

TBC

Partner to be announced

16:40 – 17:10
Panel Discussion

Can We Make Drug Discovery Faster, Smarter & More Predictable?

  • Where current drug discovery workflows create unnecessary delays, cost and uncertainty
  • How better collaboration, data integration and decision-making can improve R&D productivity
  • What the industry needs to change to move promising programs forward with greater confidence
17:10 – 17:20

Chair Closing Remarks

Chairperson
Igor Nasonkin PhD
Igor Nasonkin PhD Co-Founder & CEO · Phythera Therapeutics, Inc
17:20 - 18:20

Happy Hour

18:20
Closing

End of Conference